Form 4 for CLNN Clene Inc.
Accepted 2023-06-20 00:00:00 ET · period of report 2023-06-16 · accession 0001562180-23-005322 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2023-06-20 | 2023-06-16 | CLNN | Gay Jonathon | Dir | P - Purchase | $0.8 | +105.6K | 105.6K | New | +$84.5K |
| DM | 2023-06-20 | 2023-06-16 | CLNN | Gay Jonathon | Dir | A - Grant | — | +211.2K | 105.6K | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-06-16 | P | A | 105,625 | $0.8 | 105,625 | I By LLC | — | — | (F1) The securities are owned by Kensington CI II, LLC. Mr. Gay is a manager of and owns a minority interest in Kensington CI II, LLC. The shares owned by Kensington CI II, LLC may be deemed to be beneficially owned by Mr. Gay. Mr. Gay disclaims all shares owned by Kensington CI II, LLC for which he does not have a pecuniary or profits interest. |
| 2 | Derivative | Warrants (Right to buy) | 2023-06-16 | A | A | 105,625 | — | 105,625 | D | $1.50 · 2023-06-16 to — | 105,625 Common Stock | (F3) The price for each Unit is $0.80; one Unit consists of one share of Common Stock of Clene, one Tranche A Warrant and one Tranche B Warrant. (F4) Kensington CI II, LLC purchased a unit consisting of one share of Common Stock of Clene Inc., one Tranche A Warrant, and one Tranche B Warrant. The Tranche B Warrant is for 105,625 shares of Common Stock of Clene Inc. at an exercise price of $1.50 per share. The Tranche B Warrant will expire on the earlier of (a) June 16, 2030, or (b) 60 days after the Food and Drug Administration accepts a New Drug Application from Clene Inc. The shares owned by Kensington CI II, LLC may be deemed to be beneficially owned by Mr. Gay. Mr. Gay disclaims all shares owned by Kensington CI II, LLC for which he does not have a pecuniary or profits interest. |
| 3 | Derivative | Warrants (Right to buy) | 2023-06-16 | A | A | 105,625 | — | 105,625 | D | $1.10 · 2023-06-16 to — | 105,625 Common Stock | (F3) The price for each Unit is $0.80; one Unit consists of one share of Common Stock of Clene, one Tranche A Warrant and one Tranche B Warrant. (F5) Kensington CI II, LLC purchased a unit consisting of one share of Common Stock of Clene Inc., one Tranche A Warrant, and one Tranche B Warrant. The Tranche A Warrant is for 105,625 shares of Common Stock of Clene Inc. at an exercise price of $1.10 per share. The Tranche B Warrant will expire on the earlier of (a) June 16, 2026, or (b) 60 days after the Food and Drug Administration accepts a New Drug Application from Clene Inc. The shares owned by Kensington CI II, LLC may be deemed to be beneficially owned by Mr. Gay. Mr. Gay disclaims all shares owned by Kensington CI II, LLC for which he does not have a pecuniary or profits interest. |